CD274 and neoplasm: In 2020, the State Food and Drug Administration of China officially approved atezolizumab combined with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (25), and in 2022, it officially approved atezolizumab for the detection of adjuvant therapy in patients with stage II-IIIA NSCLC who are assessed to have ≥ 1% tumor cells (TC) positive PD-L1 staining, after surgical resection, and platinum-based chemotherapy.